Cybin Inc. (NEO: CYBN)
Cybin Corp. (NEO: CYBN)
is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.
The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.
In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.
Serenity Life Sciences & Natures Journey Inc.
The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.
Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.
Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.
Partnership with the Toronto Centre for Psychedelic Science (TCPS)
Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).
“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.
“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.
Journey’s Product Monetization & Market Potential for Nutraceutical Supplements
Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.
Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.
Pharmaceutical Psychedelics
In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.
With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.
Amalgamation Agreement and Financing
Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.
In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.
To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.
Investment Considerations
- Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products.
- The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products).
- Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in pharmaceutical sales.
- The company recently announced a strategic partnership with the Toronto Centre for Psychedelic Science.
- Cybin is currently marketing a range of fungi-based supplements under its Journey brand aimed at breaking into the global non-psychedelic legal supplement market, which is valued at $25 billion annually and growing at a 9% year-over-year rate.
- The company has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year.
- Cybin recently entered an amalgamation agreement that is expected to result in the reverse takeover of Clarmin Exploration Inc. by Cybin.
- To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.
TraderPower Featured Companies
- 180 Life Sciences Corp. (NASDAQ: ATNF)
- AzurRx BioPharma Inc. (NASDAQ: AZRX)
- Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)
- Canopy Rivers Inc. (TSX.V:RIV) (OTC: CNPOF)
- CNS Pharmaceuticals Inc. (NASDAQ: CNSP)
- Creatd Inc. (NASDAQ: CRTD)
- Cybin Inc. (NEO: CYBN)
- DarioHealth Corp. (NASDAQ: DRIO)
- Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)
- Genprex Inc. (NASDAQ: (GNPX)
- Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)
- iClick Interactive Asia Group Ltd. (NASDAQ: ICLK)
- Knightscope, Inc.
- Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF)
- Net Element, Inc. (NASDAQ: NETE)
- Predictive Oncology (NASDAQ: POAI)
- Pressure BioSciences Inc. (PBIO)
- Sigma Labs Inc. (NASDAQ: SGLB)
- SRAX Inc. (NASDAQ: SRAX)
- Sustainable Green Team Ltd. (SGTM)
- The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER)
- Trxade Group Inc. (NASDAQ: MEDS)
- Wrap Technologies Inc. (NASDAQ: WRTC)
Top Small Cap Market News
- $DRIO Appoints Diabetes, Behavioral Health Experts to Scientific Advisory Board
- $SRAX Slated to Host, Present at B. Riley Securities 2021 Vision Day
- $SRAX Announces Extension of BIGtoken Special Dividend
- $CNSP Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients
- $CNSP CEO Appears on C3 Chat Show Podcast
- $POAI Secures $3.074M in Registered Direct Offering
- $RACMF Announces Film Bubble Partnership, New CFO Appointment
- $RACMF Enters Strategic Agreement with Leading UK Pharmacy Solutions Provider
- $UUUU to Present at NobleCon17 on Tuesday, January 19, 2021
- $GNPX Slated to Present at NobleCon17
- $ICLK 52-Week High Recently Eclipsed
- $POAI Subsidiary Sells Media to Top Research Medical Centers
Recent Posts
- $POAI Subsidiary Sells Media to Top Research Medical Centers
- $ICLK 52-Week High Recently Eclipsed
- $GNPX Slated to Present at NobleCon17
- $UUUU to Present at NobleCon17 on Tuesday, January 19, 2021
- $RACMF Enters Strategic Agreement with Leading UK Pharmacy Solutions Provider
- $RACMF Announces Film Bubble Partnership, New CFO Appointment
- $POAI Secures $3.074M in Registered Direct Offering
- $CNSP CEO Appears on C3 Chat Show Podcast
Recent Comments
Archives
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009